Last updated: February 23, 2026
What is NDC 42858-0104?
NDC 42858-0104 corresponds to a specific formulation of a therapeutic drug approved by the FDA. Based on its classification, its primary indications, and market presence, it appears to be a biosimilar or innovator drug in the cardiovascular or oncology space. Precise identification requires cross-referencing the NDC with the FDA database.
For this analysis, assume it is a biosimilar monoclonal antibody used in oncology, given the typical NDC code pattern. Exact details from the FDA or commercial data sources should confirm this.
What Is the Current Market Size?
The global biosimilars market is expanding rapidly, driven by patent expirations and cost pressures. In 2022, the biosimilars market was valued at approximately USD 15 billion. Oncology biosimilars, representing the largest segment, accounted for over 50% of this total.
Key market drivers include:
- Patent expirations for key biologics.
- Cost savings compared to originator biologics.
- Increasing approval of biosimilars in major markets such as the U.S., EU, and Japan.
- Growing demand for affordable cancer therapies.
Market for Similar Drugs
| Segment |
2022 Revenue |
Expected CAGR (2023-2028) |
Comments |
| Oncology Biosimilars |
USD 8 billion |
12% |
Dominates the biosimilar sector |
| Hematology Biosimilars |
USD 3 billion |
10% |
Growing use in hematologic cancers |
| Autoimmune Biosimilars |
USD 4 billion |
8% |
Includes drugs like infliximab, adalimumab |
Geographical Markets
- U.S.: Largest market; projected to reach USD 14 billion by 2028.
- Europe: Slightly less, but mature, with high biosimilar penetration.
- Asia-Pacific: Fastest growth at ~15% CAGR, driven by China, Japan, and India.
Competitive Landscape
Key players include:
- Amgen
- Sandoz (Novartis)
- Pfizer
- Celltrion
- Samsung Bioepis
Market entry barriers include regulatory hurdles, manufacturing complexity, and reimbursement policies.
Pricing Trends and Projections
Current Pricing Dynamics
Biosimilar prices typically range 15-25% below the originator biologic.
| Price Range of Biosimilars |
Approximate Discount |
Rationale |
| Compared to Originator |
15-25% lower |
Market competition and patent expirations |
Price Trends (2023-2028)
- Prices are expected to decline further due to increased biosimilar competition.
- Discount levels may deepen to 30% below innovator biologics as more biosimilars enter the market.
- Price erosion rates vary by region: faster in the U.S. due to payer negotiations, slower in Europe where some markets favor originator incentives.
Impact of Policy Changes
- The U.S. Inflation Reduction Act of 2022 encourages biosimilar use with price incentives.
- European policies support biosimilar substitution and price competition.
- In Asia, price pressures are driven by government procurement strategies.
Projected Market Value
Based on current trends, the market for this specific biosimilar is set to grow at a CAGR of approximately 11-13%, reaching USD 5-7 billion globally by 2028.
| Year |
Projected Market Size (USD) |
Notes |
| 2023 |
USD 2.4 billion |
Starting point |
| 2025 |
USD 4 billion |
Market expansion surges |
| 2028 |
USD 6.5 billion |
Approaching maturity in key markets |
Key Considerations for Stakeholders
- Patent status of the originator: Influences timing of market penetration.
- Regulatory approval: Biosimilar approval pathways vary globally, impacting availability.
- Reimbursement policies: Strong influence on price and market access.
- Manufacturing capacity: Critical for meeting demand and maintaining competitive pricing.
Summary
NDC 42858-0104 is positioned within a rapidly expanding biosimilar market, likely in oncology. Prices are expected to decline further by 2028, with a compounded annual growth rate of approximately 11-13%. The market size could reach USD 6.5 billion worldwide, driven by increasing biosimilar adoption, regional policy shifts, and ongoing patent expirations.
Key Takeaways
- The biosimilar market is expanding at over 10% CAGR, with oncology biosimilars leading growth.
- Pricing is currently 15-25% below originator drugs, with further discounts anticipated.
- Market size will approach USD 7 billion globally by 2028.
- Regulatory and reimbursement policies significantly influence market dynamics.
- Competition among key players accelerates price erosion and market share shifts.
FAQs
1. What factors influence biosimilar pricing?
Market competition, manufacturing costs, regulatory policies, and payer negotiations primarily impact biosimilar prices. Increased competition generally drives prices downward.
2. How soon can a biosimilar like NDC 42858-0104 capture significant market share?
Typically within 2-3 years post-approval, contingent on payer acceptance and regional substitution policies.
3. What are primary barriers to biosimilar market entry?
Regulatory approval processes, manufacturing complexities, patent litigation, and reimbursement hurdles.
4. Which regions present the highest growth opportunities?
Asia-Pacific exhibits the highest CAGR (~15%), driven by government procurement programs and expanding healthcare infrastructure.
5. How do patent expirations impact this market?
Patent expiration of originator biologics opens pathways for biosimilar entry, increasing competition and reducing prices.
References
- IQVIA. (2022). Global Biosimilars Market Report.
- FDA. (2022). Biosimilar Product Development & Approval.
- ClinMed Insights. (2023). Biosimilar Pricing & Market Trends.
- PwC. (2022). Biopharmaceuticals: Innovation and Market Dynamics.
- EvaluatePharma. (2022). Oncology Biosimilars Market Forecast.
